Harmonic Discovery, a New York City-based therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, launched with $8 million in seed funding.
The round was led by Innovation Endeavors with participation from Fifty Years, Y Combinator, Boom Capital, Caffeinated Capital and select angel investors. Dr. Joel Dudley, PhD, Partner at Innovation Endeavors, joins as a new Board Member.
The company intends to use the funds to advance its drug discovery platform and pipeline by expanding its leadership team, building proprietary chemical libraries, and scaling its laboratory operations.
Founded in 2021 by Rayees Rahman, PhD, Jason Lee, MD, and Marcel Patek, PhD, Harmonic Discovery is a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology. The company’s platform leverages multiple layers of kinase biology to design safer and more efficacious kinase therapeutics. Its models learn from the topology of atoms and bonds that make up a kinase drug, to the three-dimensional ins and outs of kinase structure, all the way up to the dynamic cellular environments of disease driven by kinases. By spanning multiple disciplines, including systems biology, cheminformatics, medicinal chemistry, and machine learning, the company can develop novel therapies across diseases such as cancer and autoimmune disorders.
Harmonic Discovery is a resident of JLABS @ NYC, part of Johnson & Johnson Innovation’s global network of life science incubators.
Its Scientific Advisory Board includes Drs. Olivier Elemento, PhD, Professor of Systems Biology at Weill Cornell College of Medicine, Omar Abel-Wahab, MD, Director of the Memorial Sloan Kettering Center for Hematologic Malignancies, Tero Aittokallio, PhD, Professor of Computational Biology at the University of Oslo, and Andreas Bender, PhD, Professor of Chemoinformatics, Cambridge University and CSO of Terra Lumia.
FinSMEs
08/09/2022